




Cancer Research

AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



August 1, 1998
Volume 58 • Number 15
PP. 3193-3489
ISSN 0008-5472 • CNREA 8



1999 AACR-Pezcoller International Award for Cancer Research



Fondazione
PEZCOLLER
Trento - Italy

AACR-Pezcoller International Award Committee

Peter K. Vogt, Ph.D., *Chairperson*, Scripps Research Institute, La Jolla, USA
Franco Cavalli, M.D., Ospedale San Giovanni, Bellinzona, Switzerland
Gertrude B. Elion, D.Sc., Glaxo Wellcome, Inc., Research Triangle Park, USA
Richard D. Kolodner, Ph.D., Ludwig Institute for Cancer Research, La Jolla, USA
Alex Matter, M.D., Novartis Pharma AG, Basel, Switzerland
Marco A. Pierotti, Ph.D., Istituto Nazionale Tumori, Milan, Italy
Masaaki Terada, M.D., D.M.Sc., National Cancer Center Research Institute, Tokyo, Japan
Bengt Westermark, Ph.D., University of Uppsala, Uppsala, Sweden
Ex officio
David M. Livingston, M.D., Dana-Farber Cancer Institute, Boston, USA
Enrico Mihich, M.D., Roswell Park Cancer Institute, Buffalo, USA

The AACR-Pezcoller International Award for Cancer Research is given annually to a scientist who has made a major scientific discovery in the field of cancer, who continues to be active in the field, and whose ongoing work holds promise for future contributions to cancer research. The Pezcoller Foundation was established in 1982 by Professor Alessio Pezcoller, a dedicated Italian surgeon who has made important contributions to medicine during his career and who, through his foresight, vision, and generous gift in support of the formation of the Foundation, stimulated others to make significant advances in cancer research. Over the past decade the Pezcoller Foundation has given a major award for outstanding contributions to cancer and cancer-related biomedical science.

The American Association for Cancer Research (AACR) was founded in 1907 by eleven physicians and scientists dedicated to the conquest of cancer and now has nearly 14,000 members in more than 60 countries who are experts in basic, clinical, and translational cancer research. The mission of the AACR is to foster cancer research; this is accomplished in part through outstanding scientific publications, meetings, and training and educational programs. Because of the commitment of the Foundation and the AACR to scientific excellence in cancer research, these two organizations are collaborating annually on the presentation of the AACR-Pezcoller Award. This jointly sponsored award will strengthen international collaborations and will be a catalyst for advancements in cancer research internationally. The awardee will be selected by an international committee of AACR members appointed by the AACR President along with the agreement of the Council of the Pezcoller Foundation. While normally the Award will be presented to a single investigator, in exceptional cases two individuals may be selected to share the award when their investigations have resulted in related prizeworthy work. The committee will make its selection solely on the basis of the awardee's scientific accomplishments without regard to race, gender, nationality, or religious or political views. The candidate will give an award lecture during the AACR Annual Meeting in Philadelphia, USA (April 10-14, 1999) and will receive the award in an official ceremony at the Foundation's headquarters in Trento, Italy, after the annual meeting. The award consists of an honorarium of US\$75,000 and a commemorative plaque.

The Pezcoller Foundation and the AACR are now soliciting nominations for the 1999 Award. Nominations can be made by any scientist who is now or has been affiliated with an institution engaged in cancer research. Institutions or organizations are not eligible for this award, and candidates may not nominate themselves.


There is no official application form for this award. The nomination package should consist of the following:

- the candidate's curriculum vitae and full list of published works
- an indication of the candidates's most important publications
- a letter of recommendation in English (500 words, maximum) explaining why the candidate is deserving of this prestigious Award. This letter should summarize the candidate's major scientific achievements, indicate which of the candidate's publications best describe these achievements, and explain the impact of these achievements on progress in cancer research.

Nominators are asked to maintain the confidentiality of the nomination process and to refrain from informing the candidate about the nomination.

The deadline for receipt of nominations for the 1999 Award is **October 1, 1998**. Questions about the nomination process should be directed to the AACR via FAX at (215) 440-9322 or E-mail at aacr@aacr.org. Nominations should be submitted to the AACR. Please forward the original nomination letter plus 15 copies of the letter and any accompanying materials to:

Peter K. Vogt, Ph.D., Chairperson, Selection Committee
AACR-Pezcoller International Award for Cancer Research
c/o American Association for Cancer Research
Public Ledger Building, Suite 826
150 S. Independence Mall West
Philadelphia, PA 19106-3483
USA



Featured on this issue's cover of *Cancer Research* is Robert A. Kyle, a hematologist who is internationally recognized for his work on monoclonal gammopathies. He is a native of Bottineau, ND, and a graduate of Northwestern University Medical School in Chicago, having received his M.D. in 1952. He came to the Mayo Clinic in 1953 for a residency in Internal Medicine. After 2 years of military service and further training at Mayo, he became a Research Fellow in Hematology at Tufts University School of Medicine with Dr. William Dameshek in Boston, followed by a one year postdoctoral fellowship at the NCI. He became a consultant in Internal Medicine and Hematology at the Mayo Clinic in 1961, a Professor of Medicine at Mayo Medical School in 1975, and then a Professor of Laboratory Medicine there in 1981.

Dr. Kyle has spent his career focusing on the diagnosis, natural history, and treatment of plasma cell disorders. He developed a clinical immunology laboratory to diagnose monoclonal proteins and cryoglobulins, and the lab currently analyzes over 25,000 serum and urine specimens per year.

In 1978, he coined the term MGUS (monoclonal gammopa-

thy of undetermined significance), and he continues to study this disorder and its conversion to overt multiple myeloma. In 1980, he described smoldering multiple myeloma (SMM), another important plasma cell proliferative disorder. He has contributed to studies of the treatment of myeloma through his leadership of the Myeloma Committee of the Eastern Cooperative Oncology Group. His contributions to the study of primary systemic amyloidosis are unparalleled. He described the natural history of this disease and conducted some of the first randomized clinical trials demonstrating the effectiveness of alkylator-based chemotherapy at improving survival.

Although the focus of Dr. Kyle's work has been on monoclonal gammopathies, he has also contributed to other areas of hematology. He was one of the first to describe melphalan-induced acute nonlymphocytic leukemia. Other areas of interest include pseudoaddison's syndrome from busulfan, benign idiopathic neutropenia, and hematologic manifestations of arsenic poisoning.

Dr. Kyle has published or co-authored 485 research papers, book chapters, and films. He is a member of several professional societies, including the American Society of Hematology, the New York Academy of Sciences, the American Association for the Advancement of Science, and the American Association for Cancer Research, which he joined in 1966. He has held numerous lectureships and received several awards, such as the Mayo Distinguished Clinician Award and the Waldenstrom Award for Myeloma Research.

This brief summary of Dr. Kyle's career would not be complete without commenting on his contributions to stamp collecting and education. For many years, he has published, along with M. A. Shampo, a weekly vignette on postage stamps dealing with medical issues for the *Journal of the American Medical Association*. In the area of education, Dr. Kyle has trained countless hematologists from around the world in the diagnosis and treatment of diseases of the blood. He is a stimulating teacher whose love for medicine and scholarship is contagious, and all who know him can attest to his willingness to share his knowledge with others for the betterment of patient care.

We are indebted to his colleagues at the Mayo Clinic for providing the photograph and information for this cover feature.

Sidney Weinhouse